TG-46

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 563546

CAS#: 936091-15-5

Description: TG-46 is an inhibitor of JAK2, FLT3, RET, JAK3.

Chemical Structure

img
TG-46
CAS# 936091-15-5
Instruction

Theoretical Analysis

MedKoo Cat#: 563546
Name: TG-46
CAS#: 936091-15-5
Chemical Formula: C26H34N6O3S
Exact Mass: 510.24
Molecular Weight: 510.650
Elemental Analysis: C, 61.15; H, 6.71; N, 16.46; O, 9.40; S, 6.28

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: TG-46; TG 46; TG46;

IUPAC/Chemical Name: N-tert-Butyl-3-[[5-methyl-2-[4-(morpholin-4-ylmethyl)anilino]pyrimidin-4-yl]amino]benzenesulfonamide

InChi Key: MMXZBJJTHQWMEN-UHFFFAOYSA-N

InChi Code: InChI=1S/C26H34N6O3S/c1-19-17-27-25(29-21-10-8-20(9-11-21)18-32-12-14-35-15-13-32)30-24(19)28-22-6-5-7-23(16-22)36(33,34)31-26(2,3)4/h5-11,16-17,31H,12-15,18H2,1-4H3,(H2,27,28,29,30)

SMILES Code: O=S(C1=CC=CC(NC2=NC(NC3=CC=C(CN4CCOCC4)C=C3)=NC=C2C)=C1)(NC(C)(C)C)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 510.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kim EY, Lee JW, Lee MY, Kim SH, Mok HJ, Ha K, Ahn YM, Kim KP. Serum lipidomic analysis for the discovery of biomarkers for major depressive disorder in drug-free patients. Psychiatry Res. 2018 Jul;265:174-182. doi: 10.1016/j.psychres.2018.04.029. Epub 2018 Apr 25. PubMed PMID: 29719272.

2: Belkoff L, Brock G, Carrara D, Neijber A, Ando M, Mitchel J. Efficacy and safety of testosterone replacement gel for treating hypogonadism in men: Phase III open-label studies. Andrologia. 2018 Feb;50(1). doi: 10.1111/and.12801. Epub 2017 Mar 10. PubMed PMID: 28295450.

3: Al Faris NA, Al Othman ZA, Ahmad D. Effects of Mesembrrybryanthemum forsskalei Hochst seeds in lowering glucose/lipid profile in streptozotocin-induced diabetic rats. J Food Sci Technol. 2011 Oct;48(5):616-21. doi: 10.1007/s13197-010-0152-8. Epub 2010 Nov 5. PubMed PMID: 23572796; PubMed Central PMCID: PMC3551122.

4: Quraishi SA, Schuler GH, Janicki PK. 5 HT(3)-receptor antagonists and cardiac repolarization time in patients expressing a novel genetic target associated with baseline QTc interval abnormalities. J Clin Anesth. 2011 Jun;23(4):297-302. doi: 10.1016/j.jclinane.2010.11.003. PubMed PMID: 21663814.

5: Kipnes MS, Roth EM, Rhyne JM, Setze CM, Lele A, Kelly MT, Sleep DJ, Stolzenbach JC. Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study. Clin Drug Investig. 2010;30(1):51-61. doi: 10.2165/11319800-000000000-00000. PubMed PMID: 19995098.

6: Fregolente PB, Pinto GM, Wolf-Maciel MR, Filho RM. Monoglyceride and diglyceride production through lipase-catalyzed glycerolysis and molecular distillation. Appl Biochem Biotechnol. 2010 Apr;160(7):1879-87. doi: 10.1007/s12010-009-8822-6. Epub 2009 Oct 28. PubMed PMID: 19862491.

7: Oury C, Daenens K, Hu H, Toth-Zsamboki E, Bryckaert M, Hoylaerts MF. ERK2 activation in arteriolar and venular murine thrombosis: platelet receptor GPIb vs. P2X. J Thromb Haemost. 2006 Feb;4(2):443-52. PubMed PMID: 16420578.

8: Bove CM, Yang Z, Gilson WD, Epstein FH, French BA, Berr SS, Bishop SP, Matsubara H, Carey RM, Kramer CM. Nitric oxide mediates benefits of angiotensin II type 2 receptor overexpression during post-infarct remodeling. Hypertension. 2004 Mar;43(3):680-5. Epub 2004 Jan 19. PubMed PMID: 14732725.

9: Sheikh-Bagheri D, Rogers DW. Sensitivity of megavoltage photon beam Monte Carlo simulations to electron beam and other parameters. Med Phys. 2002 Mar;29(3):379-90. PubMed PMID: 11930913.

10: Rong N, Ausman LM, Nicolosi RJ. Oryzanol decreases cholesterol absorption and aortic fatty streaks in hamsters. Lipids. 1997 Mar;32(3):303-9. PubMed PMID: 9076667.

11: Imamura H, Tanaka K, Hirae C, Futagami T, Yoshimura Y, Uchida K, Tanaka A, Kobata D. Relationship of cigarette smoking to blood pressure and serum lipids and lipoproteins in men. Clin Exp Pharmacol Physiol. 1996 May;23(5):397-402. PubMed PMID: 8713678.

12: Rastogi SK, Gupta BN, Husain T, Mathur N. Cardio-respiratory studies on glass bangle workers. Int Arch Occup Environ Health. 1989;61(7):487-93. PubMed PMID: 2777393.

13: Taskinen MR, Beltz WF, Harper I, Fields RM, Schonfeld G, Grundy SM, Howard BV. Effects of NIDDM on very-low-density lipoprotein triglyceride and apolipoprotein B metabolism. Studies before and after sulfonylurea therapy. Diabetes. 1986 Nov;35(11):1268-77. PubMed PMID: 3530855.